In announcement no. 15-09 of 7 May 2009, NeuroSearch announced the launch of a
share purchase programme under which the company will buy own shares for an
amount of up to DKK 50 million during 2009.
The programme is structured according to European Commission Regulation No
2273/2003 of 22 December 2003, also referred to as the “Safe Harbour” rules,
for the purchase of own shares.
In the past week, since the issue of status announcement no. 23-09, the
following transactions have been made under NeuroSearch's share purchase
programme:
Accumulated share purchase / Number of shares / Average price (DKK) /
Transaction value (DKK)
15 June 2009 3,700 113.85 421,245
16 June 2009 3,000 113.95 341,850
17 June 2009 9,000 109.82 988,380
18 June 2009 400 105.50 42,200
19 June 2009 3,000 109.26 327,780
Total 19,100 111.07 2,121,455
With the purchased amount of shares as stated above, NeuroSearch now holds a
total of 123,376 treasury shares of DKK 20 nominal value each, corresponding to
0.76% of the total number of 16,274,030 issued shares in NeuroSearch A/S.
An amount of DKK 36,729,791 remains to be used under the share purchase
programme. Based on the closing price for NeuroSearch shares on NASDAQ OMX
Copenhagen on Friday 19 June 2009, this corresponds to a maximum of 338,523
additional NeuroSearch shares to be bought under the programme.
Flemming Pedersen
CEO
Contact persons:
Flemming Pedersen, CEO, telephone: +45 4460 8214 or +45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4017 5103
About NeuroSearch
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company and GlaxoSmithKline (GSK), and
license collaboration with Abbott. The drug pipeline comprises seven clinical
(Phase I-III) development programmes: Pridopidine (ACR16) for Huntington's
disease (Phase III), tesofensine for obesity (Phase III ready), ABT-894 for
ADHD (Phase II) in partnership with Abbott, ACR325 to treat dyskinesias in
Parkinson's disease (Phase II ready), ACR343 for schizophrenia (Phase I),
ABT-560 for the treatment of cognitive dysfunctions (Phase I) in collaboration
with Abbott and NSD-788 for anxiety (Phase I). In addition, NeuroSearch has a
broad portfolio of preclinical drug candidates and holds equity interests in
several biotech companies.
